%0 Journal Article
%A Driessen, M T
%A Whalen, J
%A Buguth, B Seewoodharry
%A Vallejo-Aparicio, L A
%A Naya, I P
%A Asukai, Y
%A Alcázar-Navarrete, B
%A Miravitlles, M
%A García-Río, F
%A Risebrough, N A
%T Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective.
%D 2019
%U http://hdl.handle.net/10668/13475
%X Following publication of the original article [1], we have been notified of the below corrections to the 5th paragraph in the Discussion section.
%~